$612 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 59 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVEO | Exit | AVEO PHARMACEUTICALS INCcall | $0 | – | -12,000 | -100.0% | -0.01% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INCput | $0 | – | -2,500 | -100.0% | -0.01% | – |
| TGTX | Exit | TG THERAPEUTICS INCcall | $0 | – | -10,000 | -100.0% | -0.02% | – |
| NEOS | Exit | NEOS THERAPEUTICS INCput | $0 | – | -25,000 | -100.0% | -0.05% | – |
| LXRX | Exit | LEXICON PHARMACEUTICALS INCput | $0 | – | -32,500 | -100.0% | -0.06% | – |
| AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -124,338 | -100.0% | -0.07% | – |
| EVH | Exit | EVOLENT HEALTH INCcall | $0 | – | -32,500 | -100.0% | -0.08% | – |
| ONCE | Exit | SPARK THERAPEUTICS INCput | $0 | – | -10,000 | -100.0% | -0.10% | – |
| MDXG | Exit | MIMEDX GROUP INCput | $0 | – | -50,000 | -100.0% | -0.12% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -43,900 | -100.0% | -0.12% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INCcall | $0 | – | -46,300 | -100.0% | -0.12% | – |
| EVTC | Exit | EVERTEC INCput | $0 | – | -55,000 | -100.0% | -0.14% | – |
| ATRA | Exit | ATARA BIOTHERAPEUTICS INCput | $0 | – | -55,000 | -100.0% | -0.19% | – |
| IMDZ | Exit | IMMUNE DESIGN CORP | $0 | – | -274,100 | -100.0% | -0.20% | – |
| MDCO | Exit | MEDICINES COcall | $0 | – | -40,000 | -100.0% | -0.21% | – |
| VRAY | Exit | VIEWRAY INCcall | $0 | – | -120,000 | -100.0% | -0.21% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INCput | $0 | – | -52,500 | -100.0% | -0.22% | – |
| NEOS | Exit | NEOS THERAPEUTICS INCcall | $0 | – | -115,500 | -100.0% | -0.22% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -152,300 | -100.0% | -0.26% | – |
| TDOC | Exit | TELADOC INCput | $0 | – | -40,000 | -100.0% | -0.26% | – |
| EXEL | Exit | EXELIXIS INCcall | $0 | – | -50,000 | -100.0% | -0.29% | – |
| SGEN | Exit | SEATTLE GENETICS INCput | $0 | – | -30,000 | -100.0% | -0.30% | – |
| STML | Exit | STEMLINE THERAPEUTICS INCcall | $0 | – | -105,000 | -100.0% | -0.31% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INCcall | $0 | – | -86,000 | -100.0% | -0.31% | – |
| JUNO | Exit | JUNO THERAPEUTICS INCcall | $0 | – | -37,000 | -100.0% | -0.32% | – |
| NKTR | Exit | NEKTAR THERAPEUTICSput | $0 | – | -30,000 | -100.0% | -0.34% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGcall | $0 | – | -80,000 | -100.0% | -0.36% | – |
| EDIT | Exit | EDITAS MEDICINE INCcall | $0 | – | -64,000 | -100.0% | -0.37% | – |
| VRX | Exit | VALEANT PHARMACEUTICALS INTLcall | $0 | – | -100,000 | -100.0% | -0.39% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL INcall | $0 | – | -46,000 | -100.0% | -0.40% | – |
| NKTR | Exit | NEKTAR THERAPEUTICScall | $0 | – | -36,000 | -100.0% | -0.41% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -92,500 | -100.0% | -0.43% | – |
| AGIO | Exit | AGIOS PHARMACEUTICALS INCput | $0 | – | -40,000 | -100.0% | -0.43% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INCcall | $0 | – | -80,000 | -100.0% | -0.46% | – |
| LOXO | Exit | LOXO ONCOLOGY INCput | $0 | – | -30,000 | -100.0% | -0.48% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -90,000 | -100.0% | -0.51% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INcall | $0 | – | -80,000 | -100.0% | -0.59% | – |
| SGEN | Exit | SEATTLE GENETICS INCcall | $0 | – | -80,000 | -100.0% | -0.81% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -311,169 | -100.0% | -0.82% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -900,000 | -100.0% | -0.83% | – |
| EVH | Exit | EVOLENT HEALTH INCcl a | $0 | – | -420,000 | -100.0% | -0.98% | – |
| EDGE | Exit | EDGE THERAPEUTICS INC | $0 | – | -943,906 | -100.0% | -1.67% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -300,000 | -100.0% | -2.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.